Roche data shows stomach-churning side effects of weight-loss drugs
The novel drugs work by mimicking the gut hormone GLP-1, which lowers blood sugar and limits the appetite. Treatments such as Eli Lilly’s Mounjaro also add another gut hormone, GIP, that appears to enhance weight loss. In addition, companies are experimenting with other gut and pancreatic hormones.
The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...
The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...
Terns Pharmaceuticals’ weight-loss pill has proved effective in a small trial, but still has much to prove before it can ...
On the heels of Terns’ positive Phase I results that analysts compared with Lilly’s and Pfizer’s weight loss pills in ...
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...
The current state of weight-loss treatments is about to shift with the forthcoming availability of GLP-1 drugs in the ...
The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that delivered weight loss success by taking a daily pill.
As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback